The European Medicines Agency (EMA) will provide up to five selected advanced therapy medicinal products (ATMPs) with enhanced regulatory support - and in the process hopes to learn how to improve the regulatory processes for other ATMP drugs in the future.
The Cell and Gene Therapy Catapult and Deep Science Ventures have formed a partnership aimed at creating innovative approaches to address barriers in the Advanced Therapy Medicinal Products (ATMP) industry.
Special Edition: Reviewing the advanced therapy pipeline
Atara Biotherapeutics is working on harnessing Epstein-Barr Virus (EBV) T-cells to help develop a new therapy for multiple sclerosis: saying the first-of-its-kind T-cell immunotherapy could not only slow decline but also help patients regain function...
Special Edition: Reviewing the advanced therapy pipeline
2021 could set a record in new product approvals in regenerative medicines and advanced therapies; alongside unprecedented levels of financing. And it’s a trend that looks to continue given the volume of trials ongoing worldwide, according to the Alliance...
The number of advanced therapy medicinal product (ATMP) clinical trials in the UK continues to increase year on year with 154 ongoing trials observed in 2020, demonstrating the appeal of that market for the clinical development of ATMPs, shows a new report.